ArticleSAGE open medical case reports2022
Midodrine to optimize heart failure therapy in patients with concurrent hypotension.
Article in SAGE open medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Real-World Experience of Midodrine in Hospital Setting in Pulmonary Arterial Hypertension.CHEST pulmonary · 2026Article
- Concerns Regarding Midodrine Utilization in Cancer Patients with Heart Failure.Cardiovascular drugs and therapy · 2026Article
- Response to: Concerns Regarding Midodrine Utilization in Cancer Patients with Heart Failure.Cardiovascular drugs and therapy · 2026Article
- Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study.Frontiers in pharmacology · 2024Article
- Use of midodrine in heart failure: a review.Annals of medicine and surgery (2012) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the Centers for Disease Control and Prevention statistics, about 6.2 million adults in the United States have heart failure. Guideline-Directed Medical Therapy (GDMT) involving the use of renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors serve as the backbone for heart failure with reduced ejection fraction (HFrEF) therapy. However, in patients with refractory hypotension, the initiation of GDMT may not be possible. We present four cases where the use of midodrine, an alpha adrenergic agonist, serves as bridge therapy for the initiation or continuation of GDMT with marked clinical improvement. These cases illustrate how exacerbations of HFrEF may be ameliorated with outpatient midodrine titration among patients with baseline, persistent hypotension such that GDMT may be better tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.